Assessing the Value of Next Generation Sequencing in NSCLC

Speaker(s)

Mathews C1, Niphadkar U1, Huffstater T1, Andukuri A1, Im O1, Sheppard E2, Ahmed T2, Chandra N2, Dunlop W2
1ClearView HealthCare Partners, Newton, MA, USA, 2AstraZeneca, Cambridge, UK

OBJECTIVES: Next-generation sequencing (NGS) has emerged as a powerful diagnostic tool in precision oncology, enabling personalized treatment for cancer patients. However, the value proposition of NGS is complex and multifaceted, making it challenging to fully understand and quantify. We conducted a targeted review of the clinical and economic impacts of comprehensive testing (CT) via NGS in non-small cell lung cancer (NSCLC).

METHODS: We reviewed select literature focused on the five largest European countries to assess available data on the clinical and economic value of CT in NSCLC (e.g., improved decision making, outcomes, accuracy, cost-effectiveness). Secondary resources included retrospective analyses of empirical data and model-based projections of the impact of CT versus sequential or single-gene methods.

RESULTS: We identified studies that implemented systematic analysis and review of the economic value of CT compared to sequential or single gene testing. These studies demonstrate that CT meets cost-effectiveness thresholds in these countries - the incremental cost-effectiveness ratios (ICERs) for CT versus sequential or single gene methods were under €20 – 30 K QALY which is the typical threshold in these countries. CT can also result in direct cost savings, reducing costs related to testing, hospitalization, and personnel costs by up to €5 K per patient. In many studies, CT was also associated with improved treatment decisions for NSCLC patients, resulting in longer progression-free and overall survival rates.

CONCLUSIONS: Significant progress has been made in recent years in terms of defining and articulating the value of NGS-based CT. Adoption of NGS has the potential to substantially improve patient outcomes and reducing healthcare costs. Overall, this research highlights the importance of understanding the value of NGS to optimize its use and improve patient outcomes in NSCLC. However, additional challenges associated with early-stage disease should also be evaluated to determine the utility of NGS across NCSLC stages.

Code

EE739

Topic

Economic Evaluation, Medical Technologies, Study Approaches

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Diagnostics & Imaging, Literature Review & Synthesis

Disease

Oncology, Personalized & Precision Medicine